Komori
Share Issuance and Disposal4591RIBOMIC Inc.Pharmaceuticals

Notice Regarding the Monthly Exercise Status of the 19th Series of Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Clause)

In September 2026, 2,600 Series 19 Stock Acquisition Rights were exercised and 260,000 new shares were delivered. The number of unexercised rights stood at 85,000 (representing 8,500,000 shares) at month-end.

Worth reading
64In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
260000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly exercise status of the 19th Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment Clause)

Who receives how much

Shares delivered during the month: 260,000 shares (260,000 new shares and 0 transferred treasury shares)

EVO FUND (the allottee at the time of issuance on 8 August 2025)

The lower thin line represents the existing number of shares to which these shares will be added.

Existing Shares and Increase
+0.60%Rate of increase
56,572,640 shares56,832,640Shares

Exercise ratio subject to the exercise limit: 0.6% (260,000 shares / 44,613,940 shares)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Exercise prices during the month: ¥77, ¥78, ¥80, ¥83, ¥84 and ¥95. The lower limit under the adjustment clause is Not disclosed
Number of Stock Acquisition Rights
Total issued: 110,000 rights; exercised during the month: 2,600 rights; unexercised at the end of the preceding month: 87,600 rights; unexercised at month-end: 85,000 rights
Most recent equity financing
Timing 8 August 2025 / Type Series 18 through Series 20 Stock Acquisition Rights through third-party allotment (with exercise price adjustment clauses) / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly exercise status of the 19th Stock Acquisition Rights issued through a third-party allotment (with Exercise Price Adjustment Clause)
Number of shares to be issued or disposed ofShares delivered during the month: 260,000 shares (260,000 new shares and 0 transferred treasury shares)
Intended allotteeEVO FUND (the allottee at the time of issuance on 8 August 2025)
Dilution RateExercise ratio subject to the exercise limit: 0.6% (260,000 shares / 44,613,940 shares)
Total number of issued shares56,572,640 shares (at the end of the month preceding the target month) → 56,832,640 shares (calculated as of the end of the target month)(Approximately 0.5%)
Exercise priceExercise prices during the month: ¥77, ¥78, ¥80, ¥83, ¥84 and ¥95. The lower limit under the adjustment clause is Not disclosed
Number of Stock Acquisition RightsTotal issued: 110,000 rights; exercised during the month: 2,600 rights; unexercised at the end of the preceding month: 87,600 rights; unexercised at month-end: 85,000 rights
Most recent equity financingTiming 8 August 2025 / Type Series 18 through Series 20 Stock Acquisition Rights through third-party allotment (with exercise price adjustment clauses) / Amount Not disclosed
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Exercise resumed on 24 September because the exercise suspension period expired on 18 September 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Monthly Exercise Status of the 19th Series of Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Clause) | RIBOMIC Inc. (4591) timely disclosure | Komori